Stocks TradingCharts.com

stocks prices, charts & quotes

Free Stock Prices, Charts & Stock Price Quotes

Search
Symbol Search Browse Symbols My Charts Menu
QUICK QUOTE
QUICK CHART
F.A.Questions Suggestion Box Advertising Info Commodity Charts Forex Markets

Stocks & Financial News

Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts

HIMS Investor Notice: Robbins LLP Reminds Hims & Hers Health, Inc. Stockholders of the Class Action Against the Company

Jun 28, 2025 (NewMediaWire via COMTEX) --
SAN DIEGO, CA - June 28, 2025 (NEWMEDIAWIRE) -Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025. Hims operates a telehealth platform that connects consumers to licensed healthcare professionals.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Hims & Hers Health, Inc. (HIMS) Deceptively Promoted and Sold Illegitimate Versions of Wegovy®

According to the complaint, on April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of “a bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform.” However, on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, “based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.” On this news, the Company’s share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025.

Plaintiff alleges that during the class period, defendants failed to disclose to investors: (1) that Hims was engaged in the “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;” and (2) that, as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated.

What Now: You may be eligible to participate in the class action against Hims & Hers Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 25, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, clickhere.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Hims & Hers Health, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up forStock Watchtoday.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

comtex tracking

COMTEX_466744246/2549/2025-06-28T10:04:17

Do not sell my personal information

Copyright © 2025. All market data is provided by Barchart Solutions. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.